Celcuity Inc CELC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CELC is a good fit for your portfolio.
News
-
Celcuity To Present at Upcoming Needham and Stifel Investor Conferences
-
Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call
-
Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024
-
Celcuity to Participate in Cowen’s 44th Annual Health Care Conference
-
Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer
-
Celcuity Appoints Eldon Mayer as Chief Commercial Officer
Trading Information
- Previous Close Price
- $16.94
- Day Range
- $15.71–16.76
- 52-Week Range
- $8.39–22.19
- Bid/Ask
- $7.39 / $23.52
- Market Cap
- $480.25 Mil
- Volume/Avg
- 228,657 / 225,228
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company’s lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 55
- Website
- https://www.celcuity.com
Comparables
Valuation
|
Metric
|
CELC
|
VRDN
|
TGTX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 17.99 |
Price/Book Value | 2.88 | 2.91 | 13.44 |
Price/Sales | — | 1,810.15 | 9.06 |
Price/Cash Flow | — | — | 39.74 |
Price/Earnings
CELC
VRDN
TGTX
Financial Strength
|
Metric
|
CELC
|
VRDN
|
TGTX
|
|---|---|---|---|
Quick Ratio | 12.78 | 17.93 | 5.00 |
Current Ratio | 13.43 | 18.26 | 5.92 |
Interest Coverage | −12.43 | −137.76 | 2.04 |
Quick Ratio
CELC
VRDN
TGTX
Profitability
|
Metric
|
CELC
|
VRDN
|
TGTX
|
|---|---|---|---|
Return on Assets (Normalized) | −35.57% | −42.76% | 19.44% |
Return on Equity (Normalized) | −49.08% | −82.42% | 54.76% |
Return on Invested Capital (Normalized) | −39.21% | −50.70% | 35.76% |
Return on Assets
CELC
VRDN
TGTX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lzwllhsrfy | Xlxjx | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Whypcbdn | Qlgvf | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Bflygcjht | Yctlbt | $97.8 Bil | |
MRNA
| Moderna Inc | Fkxlqdzww | Xyjb | $38.8 Bil | |
ARGX
| argenx SE ADR | Jwywkdp | Jrgz | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Gxcjhzh | Ndt | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qptwxcjr | Ntssws | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Strbzpz | Qmxvyv | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Nbbjnckczb | Bffld | $12.5 Bil | |
INCY
| Incyte Corp | Vrjhhnyv | Mkfyv | $11.5 Bil |